secwatch.observer — SEC 8-K summary
======================================

Issuer:     Biomea Fusion, Inc. (BMEA)
CIK:        0001840439
Form:       8-K
Filed at:   2026-03-24T23:59:59+00:00
Accession:  0001193125-26-121811
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Biomea Fusion reports FY2025 net loss of $61.8M; cash runway into Q1 2027; initiates Phase II trials in diabetes
--------------------------------------------------------------------------------

- Net loss $61.8M for FY2025 vs $138.4M in FY2024; R&D expenses decreased 47% to $62.0M.
- Cash and equivalents $56.2M as of Dec 31, 2025; projected cash runway into Q1 2027.
- Initiated Phase II trials COVALENT-211 and COVALENT-212 for icovamenib in type 2 diabetes; topline data expected Q4 2026.
- Phase I trial GLP-131 (BMF-650) for obesity initiated; initial 28-day weight reduction data expected Q2 2026.
- Positive 52-week data from COVALENT-111: 1.2% mean HbA1c reduction maintained 9 months off therapy.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1840439/000119312526121811/0001193125-26-121811-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1840439/000119312526121811/bmea-20260324.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-121811

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer